TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155
CJDQ443A12101
Phase 2 small_molecule active
Quick answer
TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155 for Advance solid tumors harboring the KRAS G12C mutation is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advance solid tumors harboring the KRAS G12C mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active